Bellicum Pharmaceuticals logo
Bellicum Pharmaceuticals BLCM

Quarterly report 2023-Q3
added 11-14-2023

report update icon

Bellicum Pharmaceuticals Cash Flow 2011-2026 | BLCM

Annual Cash Flow Bellicum Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-25.8 M -23.1 M -56.6 M -77.6 M -74.8 M -73 M -50.4 M -35.7 M -57.3 M -7.61 M - -

Depreciation & Amortization

11 K 105 K 1.47 M 7.18 M 6.7 M 3.56 M 2.31 M 1.2 M 667 K 587 K - -

Accounts Payables

486 K 90 K 891 K 2.64 M 3.77 M 3.29 M 3.62 M 2.11 M - - - -

Accounts Receivables

- 205 K 2 K 303 K 909 K 320 K 334 K 440 K - - - -

All numbers in USD currency

Quarterly Cash Flow Bellicum Pharmaceuticals

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -6.43 M - -18.9 M -13 M -6.38 M - -17.1 M -16.1 M -8.29 M - -43.3 M -30.5 M -16.3 M - -64.8 M -46 M -24.6 M - -54.4 M -37.7 M -18.7 M - -60.2 M -42.6 M -22.5 M - -36 M -24.6 M -11.2 M - -23.6 M -16.2 M -7.02 M - -7.16 M -6.21 M -3.22 M - - - - - - - - - - - -

Depreciation & Amortization

- - 3 K - 9 K 8 K 5 K - 90 K 70 K 47 K - 1.23 M 925 K 537 K - 5.48 M 3.74 M 1.79 M - 4.92 M 3.16 M 1.43 M - 2.52 M 1.6 M 800 K - 1.6 M 951 K 500 K - 769 K 375 K 196 K - 485 K 321 K 159 K - - - - - - - - - - - -

Accounts Payables

526 K 472 K 1.23 M 486 K 714 K 399 K 212 K 90 K 521 K 760 K 669 K 891 K 891 K 891 K 891 K 2.64 M 2.64 M 2.64 M 2.64 M 3.77 M 3.77 M 3.77 M 3.77 M 3.29 M 3.29 M 3.29 M 3.29 M 3.62 M 3.62 M 3.62 M 3.62 M 2.11 M 2.11 M 2.11 M 2.11 M 1.21 M 1.21 M 1.21 M 1.21 M - - - - - - - - - - - -

Accounts Receivables

15 K - 8 K - 1 M 209 K 207 K 205 K 556 K 904 K 375 K 2 K 2 K 2 K 2 K 303 K 303 K 303 K 303 K 909 K 909 K 909 K 909 K 320 K 320 K 320 K 320 K 334 K 334 K 334 K 334 K 440 K 440 K 440 K - 298 K - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Bellicum Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.25 1.81 % $ 908 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.44 -16.64 % $ 5.04 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.98 1.17 % $ 3.05 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.14 -0.29 % $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
$ 0.53 -3.07 % $ 6.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 37.7 1.26 % $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.15 -0.73 % $ 4.42 B schweizSchweiz
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 2.96 -1.0 % $ 252 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 4.4 -3.51 % $ 607 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.86 0.67 % $ 5.79 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 0.18 -1.61 % $ 17.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 4.15 -32.52 % $ 10.4 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 1.81 4.02 % $ 20.2 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 20.36 -3.32 % $ 2.84 B franceFrance
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.38 -6.15 % $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
$ 0.87 -2.8 % $ 31.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.37 1.0 % $ 2.08 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA